ClinicalTrials.gg
CompletedNCT01157793Updated Jul 11, 2014

A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood

A Phase 4 interventional study of r-hGH and r-hGH in Dwarfism and Growth Hormone Deficiency, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 14 Years to 25 Years. Per ClinicalTrials.gov, last updated 2014-07-11.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
14 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Human Growth Hormone in Dwarfism — none open to participants now, 1 under way, none of them phase 3. Human Growth Hormone · Dwarfism.

Enrollment
10th of 15
34 · median 68
Started
2003
with 1 other
Phase 4
4 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
1 of 15
Merck KGaA, Darmstadt, Germany

Among the 15 studies testing Human Growth Hormone in Dwarfism, this one is the 10th largest by enrollment, is one of 2 that started in 2003, is one of 4 in phase 4, and was the 8th registered.

Dwarfism

99 studies on the registry are indexed under Dwarfism; 12 are open to participants now.

Browse Dwarfism studies →

Open to participants now

None of the 15 studies testing Human Growth Hormone in Dwarfism is open now. The open studies under Dwarfism, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Dwarfism studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 14 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Human Growth Hormone in Dwarfism as a file.
02

Study summary

This was a 48-week, open-label, prospective, multicentric, randomised, comparative with parallel control, Phase 4 study to evaluate the effects of Saizen on cardiac function in GHD subjects during the transition phase from childhood to adulthood.

The study was designed to evaluate whether recombinant-human growth hormone (r-hGH) treatment also benefits young subjects with GHD. Some trials have already been published on this subject, but they were mainly focused on the bone density.

Read the detailed description

Growth hormone is a 191 amino acid polypeptide hormone (MW 22,000) normally synthesised and secreted by the somatotrophic cells of the anterior lobe of the pituitary gland. In normal development, growth hormone and somatomedins are responsible for many of the manifestations of normal growth and GHD is manifested by a marked short stature. Growth hormone deficiency has been treated by human growth hormone for many years. Serono's r-hGH (Saizen) is produced from genetically engineered mammalian cells.

The findings from previous clinical studies on GH treatment in GH-deficient adults, collectively indicate that the majority of adults with long-standing GH deficiency, whether dating from childhood or acquired in adult life, are compromised both physically and psychologically and can derive clinical benefit from GH replacement. Based on observations in the clinical trials to date , a GH dose of 0.01 mg/kg/day (50% of the dose used in children), is likely to be satisfactory for many subjects. Moreover, it should be possible to minimise early side effects, particularly fluid retention, by initiating treatment with half of this dose and increasing to the final dose after 4 weeks if well tolerated.

In this study, it was proposed to enroll a group of childhood onset GHD subjects who were not treated with r-hGH. Half of the study population started treatment for six months whilst the other half remained on no r-hGH treatment. After six months the group already on r-hGH therapy continued treatment for a further six months and the second group presently on no r-hGH treatment started r hGH treatment for the remaining six months of the study.

OBJECTIVES

Primary objective:

  • To compare the effects of Saizen on cardiac function (as assessed by percentage ejection fraction) in subjects where 50% of the study population started r-hGH treatment for 24 weeks and then remained on r-hGH treatment for a further 24 weeks and subjects who continued on no r-hGH for 24 weeks before starting r-hGH for 24 weeks during the transition phase from childhood to adulthood.

Secondary objectives:

  • To assess the safety and tolerability of r-hGH in subjects who were transitioning from childhood to adulthood, and to assess the change in body composition and lean body mass. Subsidiary analyses of the other echocardiography parameters was also performed.

After entry into the trial, the subjects were randomised to one of two groups for a 48-week period:

  • Group 1: Saizen (r-hGH), 0.15-1.00 mg/day for 48 weeks, subcutaneous (s.c.)
  • Group 2: No treatment for the first 24 weeks followed by Saizen (r-hGH)0.15-1.00 mg/day for the next 24 weeks, s.c.

Subjects' visits to the study site was scheduled as follows:

  • Group 1 - Baseline (study day 1), weeks 4, 12, 24, 36 \& 48.
  • Group 2 - Baseline (study day 1), weeks 12, 24, 28, 36 \& 48. The study drug was administered subcutaneously once daily in the evenings during the active treatment period. The dose was to be adjusted stepwise, controlled by Insulin-Growth Factor-I (IGF-I) values. The recommended final r-hGH dose was not to exceed 1.00mg/day
03

Conditions studied

  • Dwarfism
  • Growth Hormone Deficiency

Keywords

  • Dwarfism
  • Growth hormone deficiency
  • Growth hormone
04

Who can participate

Ages eligible
14 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with diagnosis of childhood onset GH deficiency and previously treated with GH
  • Subjects who had attained final height
  • Male or female subjects, aged between 14 and 25 years of age inclusively at baseline
  • Subjects with GH deficiency of \<5μg/L (acquired or idiopathic), established by any 1 type of GH secretion test within 3 years prior to Study Day 1
  • If hypopituitary, subject must have been on adequate replacement therapy (if required) of glucocorticosteroids, thyroid \& sex hormones (hormones levels on replacement being in normal/mildly elevated range) for at least 6 months prior to study entry
  • Subjects who were willing and able to comply with the protocol for the duration of the study.
  • Subjects who had given written before any study-related procedure not part of the subject's normal medical care, with the understanding that the subject might withdraw consent at any time without prejudice to future medical care
  • Female subjects must be neither pregnant nor breast-feeding, and use a hormonal , intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Confirmation that a female subject was not pregnant was established by a negative urinary human chorionic gonadotropin (hCG) pregnancy test at baseline.

Exclusion criteria

Exclusion Criteria:

  • Subject who had a known allergy or to growth hormone or diluent
  • Subject who had been treated with r-hGH in previous six months
  • Subject with chronic severe kidney disease
  • Subject with chronic severe liver disease
  • Subject with acute or severe illness during the previous 6 months
  • Subject with significant concomitant illness which would interfere with his/her participation or assessment in this study
  • Subject with active (except non-melanomatous skin malignancies)
  • Subjects with unstable hypertension (supine systolic blood pressure persistently above 160 mmHg or diastolic blood pressure persistently above 100 mmHg)
  • Subjects with benign cranial hypertension
  • Subjects with a history of carpal tunnel syndrome, unless surgically released
  • Subjects with known positive (HIV), surface antigen (HBsAg) and/or virus (HCV) serology based on past medical history
  • Subjects with known active drug addiction, including alcoholism, or use of drugs for nontherapeutic purposes
  • Subject who had previously participated in this study
  • Subject taking an drug or enrolled in another clinical study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Group 1

    Drug: r-hGH

  • Experimental
    Group 2

    Drug: r-hGH

Interventions

  • Drugr-hGH

    r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route

    Also known as: Saizen®

  • Drugr-hGH

    Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route

    Also known as: Saizen®

06

What researchers measure

Primary outcomes

  1. Change in percentage ejection fraction in subjects during the transition phase from childhood to adulthood

    Time frame: Baseline to study week 48

Secondary outcomes

  1. Subsidiary analysis of the other echocardiography parameters and lean body mass

    Time frame: Baseline to study week 48

  2. Evaluation of laboratory parameters and monitoring of adverse events

    Time frame: Baseline to study week 48

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2010
First posted
Jul 7, 2010
Start
Sep 2003
Primary completionActual
Feb 2005
CompletionActual
Feb 2005
Last update
Jul 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01157793
First posted
Jul 7, 2010
Start date
Sep 2003
Primary completion
Feb 2005
Completion
Feb 2005
Last update
Jul 11, 2014

Study contacts

Theodor Wee, MD
study director · Merck Serono International SA

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion